A recent study from the Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; The James Cancer Hospital, The Ohio State University, Columbus, OH, USA shows that Transcription factor foxo1 is a negative regulator of NK cell maturation and function. This study was published in the 10 March 2015 issue of Immunity (the number 1 journal in the field of Immunological research with an impact factor of 19.748) by Prof Yu J, Deng Y, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small molecule-based Immune augmentation therapy: Succinate, one of the component of TCA cycle, promotes NK cell maturation and function via up regulation of its target gene.
Significance:
This study suggests, for the first time, that Succinate, by increasing the expression of its target gene, it may decrease the expression of FOXO1. Thereby, it may promote NK cell maturation and function. Thus, pharmacological formulations encompassing “Succinate or its analogues” may be used to (1) increase NK cell function; and (2) eradicate large solid tumors.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Small molecule-based Immune augmentation therapy: Succinate, one of the component of TCA cycle, promotes NK cell maturation and function via up regulation of its target gene, 13/May/2014, 11.57 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: How Succinate decreases Foxo1 expression
